Andere talen ALX Oncology Holdings Inc.

Aandelen

ALXO

US00166B1052

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
16,86 ^USD	-0,06%		+8,08%	+13,23%

18/04	Insider bij Alx Oncology Holdings verkocht aandelen ter waarde van $710.195, volgens een recent SEC-document	MT
10/04	ALX Oncology rapporteert positieve gegevens van de lopende fase 1/2-studie met evorpacept	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting	24/04
Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	18/04
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	10/04
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)	09/04
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	09/04
ALX Oncology : Corporate Presentation	11/03
North American Morning Briefing : Stock Futures -2-	11/03
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	07/03
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	05/03
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	05/03
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
ALX Oncology Holdings Inc. and ALX Oncology Inc. Enter into the Third Amendment to Loan and Security Agreement	26/12
North American Morning Briefing : Investors Await -2-	11/12
Top Midday Gainers	08/12
Sector Update: Health Care Stocks Advance Premarket Tuesday	14/11
ALX Oncology Reports Q3 Results With 'Sufficient' Funds to Finance Operations Into Early 2026	13/11
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours	13/11
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ALX Oncology Holdings Inc.

Aandelen

ALXO

US00166B1052

Andere talen

Filters